SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals announced a strategic collaboration with…

Telix Pharmaceuticals Limited · PRESS-RELEASE filed Apr 13, 2026 at 06:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 13, 2026 at 06:30 ET

Telix Pharmaceuticals announced a strategic collaboration with Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Telix will receive an upfront payment of $40 million and has the option to earn up to $2.1 billion in aggregate milestone payments plus royalties if it opts out of co-funding. The partnership combines Telix’s radiopharmaceutical expertise with Regeneron’s antibody discovery platforms.

  • Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceuticals in a 50/50 cost and profit-sharing model.
  • Telix to receive $40 million upfront from Regeneron for four initial programs.
  • If Telix opts out of co-funding for a program, it can earn up to $535 million in milestones per program, with a total potential of $2.1 billion across multiple programs, plus low double-digit royalties.
  • Collaboration includes multiple solid tumor targets using Regeneron’s VelocImmune®-derived antibodies and joint development of radio-diagnostic tools.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access